Health on MSN
The 3 Most Common GLP-1 Injection Sites
Knowing where and how to inject GLP-1s can help ensure you are safely and effectively using the medication. Common sites ...
Keytruda Qlex is now FDA-approved for subcutaneous use in patients 12 and older with solid tumors, offering an alternative to IV administration. Subcutaneous administration can improve patient ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...
LONDON, October 15, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase I ...
Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. and navigating the impact of the Inflation Reduction Act (IRA), the company has penned an acquisition of fellow ...
GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another long-acting PrEP option this summer, when rival Gilead Sciences rolled out ...
Initial data from the CLARITY study are first to compare acceptability and tolerability of single-dose cabotegravir (CAB) and lenacapavir (LEN) long-acting injections, in 63 HIV-negative adults ...
Chugai Pharmaceutical Co., Ltd. announced that it has concluded a license agreement with F. Hoffmann-La Roche Ltd (Roche) for CT-388, a long-acting GLP-1/GIP receptor agonist, currently in development ...
Eisai and Biogen have won FDA approval for a subcutaneous injection version of Leqembi that could help accelerate uptake of the Alzheimer's disease therapy. The green light for Leqembi Iqlik ...
(MENAFN- GlobeNewsWire - Nasdaq) TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback